1989
DOI: 10.1016/0006-291x(89)92529-1
|View full text |Cite
|
Sign up to set email alerts
|

Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

5
96
1
1

Year Published

1989
1989
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 197 publications
(103 citation statements)
references
References 25 publications
5
96
1
1
Order By: Relevance
“…Although this explanation might account for the decrease in glucose-induced insulin secretion, the extent of islet cell loss over the time period from addition of h-IAPP to the end of the study was insufficient to be measurable by quantitative analysis (and certainly less than the ϳ90% decrease in glucose-induced insulin secretion). An alternative explanation is the action of IAPP through its cell surface receptor to inhibit insulin secretion (39). However, any receptor-mediated actions of IAPP would be most evident with r-IAPP that would have remained monomeric in conditions of culture, in contrast to h-IAPP that would have spontaneously formed h-IAPP oligomers.…”
Section: Discussionmentioning
confidence: 99%
“…Although this explanation might account for the decrease in glucose-induced insulin secretion, the extent of islet cell loss over the time period from addition of h-IAPP to the end of the study was insufficient to be measurable by quantitative analysis (and certainly less than the ϳ90% decrease in glucose-induced insulin secretion). An alternative explanation is the action of IAPP through its cell surface receptor to inhibit insulin secretion (39). However, any receptor-mediated actions of IAPP would be most evident with r-IAPP that would have remained monomeric in conditions of culture, in contrast to h-IAPP that would have spontaneously formed h-IAPP oligomers.…”
Section: Discussionmentioning
confidence: 99%
“…Firstly, the peptide was isolated from pancreatic amyloid deposits [1] suggesting some abnormality associated with its expression. Secondly, the peptide was found to oppose the action of insulin on skeletal muscle preparations [3] and thirdly, it was found to inhibit insulin release [4]. Although there is no wholly satisfactory model for Type 2 diabetes in the rat, dexamethasone and partial streptozotocin treatment produce conditions having elements in common with this condition and these were therefore investigated using the technique of Northern blotting.…”
Section: Discussionmentioning
confidence: 99%
“…This peptide is now known as islet amyloid polypeptide (IAPP) [2], or amylin [3]. IAPP opposes the action of insulin on isolated muscle preparations [3] and inhibits insulin release from rat islets in vitro [4]. Using a cloned DNA probe representing the rat IAPP coding sequence, we have recently found IAPP to be present in the stomach as well as the pancreas [5].…”
mentioning
confidence: 99%
“…Amylin, originally identified in amyloid plaques in the pancreatic islets of Type II diabetics, may be a circulating fl-cell hormone controlled by blood glucose levels. Moreover, amylin itself has been implicated in the pathogenesis of Type II (insulin-resistant) diabetes Ohsawa et al, 1989;Nishi et al, 1990). Thus, an emerging issue is whether amylin and CGRP act on common or distinct receptors, possibly with some degree of cross-talk (Morishita et al, 1990;Nishi et al, 1990).…”
Section: Introductionmentioning
confidence: 99%